GMT Capital’s Tempest Therapeutics TPST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-272
Closed -$64K 62
2021
Q1
$64K Buy
+272
New +$110K ﹤0.01% 54
2020
Q4
Sell
-272
Closed -$87K 61
2020
Q3
$87K Hold
272
0.01% 69
2020
Q2
$93K Buy
272
+48
+21% +$19.1K 0.01% 68
2020
Q1
$231K Sell
224
-43
-16% -$62.7K 0.01% 75
2019
Q4
$351K Sell
267
-7
-3% -$9.87K 0.01% 57
2019
Q3
$380K Hold
274
0.01% 77
2019
Q2
$618K Buy
274
+201
+275% +$592K 0.02% 72
2019
Q1
$215K Sell
73
-201
-73% -$445K 0.01% 72
2018
Q4
$425K Hold
274
0.02% 69
2018
Q3
$585K Hold
274
0.02% 94
2018
Q2
$727K Hold
274
0.02% 101
2018
Q1
$650K Buy
+274
New +$821K 0.02% 93
2017
Q4
Sell
-274
Closed -$1.14M 136
2017
Q3
$1.14M Buy
+274
New +$1.17M 0.02% 115
2017
Q2
Sell
-259
Closed -$1.42M 106
2017
Q1
$1.42M Buy
259
+79
+44% +$368K 0.03% 102
2016
Q4
$807K Buy
180
+33
+22% +$411K 0.02% 121
2016
Q3
$3.08M Sell
147
-6
-4% -$109K 0.06% 101
2016
Q2
$2.33M Sell
153
-134
-47% -$3.06M 0.06% 102
2016
Q1
$7.98M Buy
+287
New +$6.07M 0.2% 72

Other funds holding TPST

GMT Capital's TPST Position: Q2 2021 in Review

GMT Capital sold out of Tempest Therapeutics (TPST) in Q2 2021, closing a stake of 272 shares — an estimated $64K sold.

GMT Capital first reported a position in TPST in Q1 2016 and held it in 18 quarters. The position peaked at $7.98M in Q1 2016. 23 funds tracked by Wall St. Rank hold TPST as of Q2 2021.

  • GMT Capital reported no remaining Tempest Therapeutics position as of Q2 2021 after selling out during the quarter.
  • GMT Capital sold 272 Tempest Therapeutics shares in Q2 2021, an estimated $64K.
  • GMT Capital first reported a position in Tempest Therapeutics in Q1 2016 and held it in 18 quarters.
  • GMT Capital's Tempest Therapeutics position peaked at $7.98M in Q1 2016.
  • 23 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2021.

Based on GMT Capital's 13F filing for Q2 2021, filed 13 Aug 2021.